The estimated Net Worth of Jacqueline Kunzler is at least $1.38 Milión dollars as of 21 February 2023. Ms. Kunzler owns over 4,163 units of Baxter International stock worth over $806,527 and over the last 5 years she sold BAX stock worth over $570,617. In addition, she makes $0 as Senior Vice President and Chief Quality Officer at Baxter International.
Jacqueline has made over 4 trades of the Baxter International stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 4,163 units of BAX stock worth $157,445 on 21 February 2023.
The largest trade she's ever made was selling 5,934 units of Baxter International stock on 5 September 2019 worth over $522,904. On average, Jacqueline trades about 717 units every 75 days since 2019. As of 21 February 2023 she still owns at least 20,538 units of Baxter International stock.
You can see the complete history of Ms. Kunzler stock trades at the bottom of the page.
Jacqueline Kunzler serves as Senior Vice President and Chief Quality Officer of the Company. Ms. Kunzler joined Baxter in 1993 and has served in roles of increasing responsibility across Baxter’s research & development, international marketing, and quality organizations, most recently as Senior Vice President, Chief Quality Officer.
Jacqueline Kunzler is 54, she's been the Senior Vice President and Chief Quality Officer of Baxter International since 2019. There are 20 older and 8 younger executives at Baxter International. The oldest executive at Baxter International Inc. is James Gavin, 74, who is the Independent Director.
Jacqueline's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney a Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: